{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:39:33Z","timestamp":1792705173911,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001721","name":"Rijksuniversiteit Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"DOI":"10.1038\/s41375-026-03156-1","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:40:39Z","timestamp":1792658439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multiple myeloma in the Netherlands: 35-year trends in incidence and survival"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8902-4162","authenticated-orcid":false,"given":"Koen M.","family":"Klomberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3976-8001","authenticated-orcid":false,"given":"Wilfried W. H.","family":"Roeloffzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-2873","authenticated-orcid":false,"given":"Marcel","family":"Nijland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2139-3547","authenticated-orcid":false,"given":"Mark-David","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inger S.","family":"Nijhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimke","family":"Oostvogels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"de Kort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1784-1765","authenticated-orcid":false,"given":"Catharina H. M. J.","family":"van Elssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther G. M.","family":"de Waal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A. F.","family":"Geerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavuz M.","family":"Bilgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djamila E.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"van de Klift","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin A.","family":"Huls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurens E.","family":"Franssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cleo R.","family":"van Rooijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemiek","family":"Broijl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-7979","authenticated-orcid":false,"given":"Paula F.","family":"Ypma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7445-2603","authenticated-orcid":false,"given":"Niels W. C. J.","family":"van de Donk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5011-1820","authenticated-orcid":false,"given":"Sonja","family":"Zweegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-4810","authenticated-orcid":false,"given":"Mirian","family":"Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter J.","family":"Plattel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,22]]},"reference":[{"key":"3156_CR1","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","volume":"22","author":"MA Dimopoulos","year":"2025","unstructured":"Dimopoulos MA, Terpos E, Boccadoro M, Moreau P, Mateos MV, Zweegman S, et al. EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. Nat Rev Clin Oncol. 2025;22:680\u2013700.","journal-title":"Nat Rev Clin Oncol"},{"key":"3156_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00571-8","volume":"11","author":"M Brink","year":"2021","unstructured":"Brink M, Groen K, Sonneveld P, Minnema MC, Broijl A, Dinmohamed AG, et al. Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study. Blood Cancer J. 2021;11:178.","journal-title":"Blood Cancer J"},{"key":"3156_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11864-000-0017-x","volume":"1","author":"N Raje","year":"2000","unstructured":"Raje N, Anderson KC. Multiple myeloma. Curr Treat Options Oncol. 2000;1:73\u201382.","journal-title":"Curr Treat Options Oncol"},{"key":"3156_CR4","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"3156_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S, Bornh\u00e4user M. Multiple myeloma. Lancet. 2015;385:2197\u2013208.","journal-title":"Lancet"},{"key":"3156_CR6","doi-asserted-by":"publisher","first-page":"60656","DOI":"10.18632\/oncotarget.19269","volume":"8","author":"A Larocca","year":"2017","unstructured":"Larocca A, Mina R, Gay F, Bringhen S, Boccadoro M. Emerging drugs and combinations to treat multiple myeloma. Oncotarget. 2017;8:60656\u201372.","journal-title":"Oncotarget"},{"key":"3156_CR7","doi-asserted-by":"publisher","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","volume":"24","author":"P Moreau","year":"2013","unstructured":"Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi133\u20137.","journal-title":"Ann Oncol"},{"key":"3156_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/17474086.2025.2490764","volume":"18","author":"SI Quezada-Ram\u00edrez","year":"2025","unstructured":"Quezada-Ram\u00edrez SI, Del Carmen Tar\u00edn-Arzaga L, G\u00f3mez-De Le\u00f3n A, G\u00f3mez-Almaguer D. Novel drug combinations for newly diagnosed multiple myeloma: how can we improve on current regimens? Expert Rev Hematol. 2025;18:359\u201372.","journal-title":"Expert Rev Hematol"},{"key":"3156_CR9","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.3324\/haematol.2023.283058","volume":"109","author":"M Engelhardt","year":"2024","unstructured":"Engelhardt M, Kort\u00fcm KM, Goldschmidt H, Merz M. Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible. Haematologica. 2024;109:2420\u201335.","journal-title":"Haematologica"},{"key":"3156_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01253-5","volume":"15","author":"JTD Souto Filho","year":"2025","unstructured":"Souto Filho JTD, Cantadori LO, Crusoe EQ, Hungria V, Maiolino A. Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Cancer J. 2025;15:37.","journal-title":"Blood Cancer J"},{"key":"3156_CR11","unstructured":"IKNL (Netherlands Comprehensive Cancer Organization). Netherlands Cancer Registry (NCR). Utrecht (The Netherlands): IKNL; 2024. Available from: https:\/\/iknl.nl\/en\/ncr. Accessed 2024."},{"key":"3156_CR12","unstructured":"Eurostat. Revision of the European Standard Population: Report of Eurostat\u2019s task force. 2013 edition. Luxembourg: Publications Office of the European Union; 2013. ISBN: 978-92-79-31094-2. Available from: https:\/\/ec.europa.eu\/eurostat\/documents\/3859598\/5926869\/KS-RA-13-028-EN.PDF"},{"key":"3156_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96804-8","volume":"11","author":"K Hemminki","year":"2021","unstructured":"Hemminki K, F\u00f6rsti A, Hansson M. Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016. Sci Rep. 2021;11:17272.","journal-title":"Sci Rep"},{"key":"3156_CR14","first-page":"703","volume":"21","author":"E Feletto","year":"2024","unstructured":"Feletto E, Luo Q, Kelly A, Weber M, Goldsbury D, Barron K, et al. Multiple myeloma survival in New South Wales, Australia, by treatment era to 2020. Cancer Biol Med. 2024;21:703\u201311.","journal-title":"Cancer Biol Med"},{"key":"3156_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1111\/bjh.18025","volume":"197","author":"D Swan","year":"2022","unstructured":"Swan D, Hayden PJ, Eikema DJ, Koster L, Sauer S, Blaise D, et al. Trends in autologous stem cell transplantation for newly diagnosed multiple myeloma: Changing demographics and outcomes in European Society for Blood and Marrow Transplantation centres from 1995 to 2019. Br J Haematol. 2022;197:82\u201396.","journal-title":"Br J Haematol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03156-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03156-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03156-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:02:07Z","timestamp":1792702927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03156-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,22]]},"references-count":15,"alternative-id":["3156"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03156-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,22]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KMK: none; WWHR: Consultancy\/honoraria: Janssen-Cilag, Celgene and Takeda; MN: Consultancy\/honoraria: Roche Pharma, Celgene and BMS; MDL: Honoraria: Janssen Pharmaceuticals; ISN: Consultancy\/honoraria: Janssen-Cilag, Kite and AbbVie. All paid to institution; RO: Consultancy\/honoraria: Janssen Pharmaceuticals and Pfizer; EdK: Consultancy\/honoraria: AbbVie, Pfizer and Gilead Sciences. All paid to institution; RW: Consultancy\/honoraria: Janssen-Cilag, Amgen, Pfizer and Celgene; CHMJvE: Consultancy\/honoraria: Janssen-Cilag, Amgen, Pfizer, Servier, Sanofi, all paid to the institution; EGMdW: none; PAFG: none; YMB: none; DEI: none; MvdK: none; GAH: none; LEF: Consultancy\/honoraria: AbbVie, Amgen and Servier; CRvR: none; MCM: Research support from Janssen Pharmaceuticals and BeOne. Advisory board for Janssen Pharmaceuticals, AMGEN, Oncopeptides Celgene, BMS, Sanofi, Takeda and GSK. All paid to institution; AB: Consultancy\/honoraria: Janssen-Cilag, Sanofi and BMS; PFY: consultancy\/honoraria AOPHealth\/Jansen-Cilag\/Incyte\/Amgen paid to the institution; NWCJvdD: Research support from Janssen Pharmaceuticals, Amgen, Celgene, Novartis, Cellectis and BMS. Served in advisory boards for Janssen Pharmaceuticals, Amgen, Celgene, BMS, Sanofi, Takeda, Roche, Novartis, Bayer, Adaptive, Merck, Kite Pharma, Pfizer, AbbVie and Servier. All paid to Institution; SZ: Research support from Janssen Pharmaceuticals and Takeda. Served in Advisory boards for Janssen Pharmaceuticals, Amgen, Oncopeptides Celgene, BMS, Sanofi, Takeda and GSK. All paid to institution; MB: none; WJP: Consultancy\/honoraria: Janssen -Cilag, Takeda and Pfizer.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}